Skip To Main Content
Anna Barton on Muck Rack

Anna Barton

As seen in: Science Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anna

Contact Anna, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine

|
By Brendon E. Cook, Christina Dold, Helen CHEN, Blanché Oguti, Meriel Raymond, Catherine Smith, Maria Moore, Anna Barton, Edward Choi, Emma L Plested, Ann Holland, Robert Cook, Jessica King, Jay Lucidarme, Ray Borrow, Blanché Oguti, Laura Silva-Reyes, Anna Stanzelova, Kiarash Tanha, Jennifer Louth
| Science Magazine Verified
Editor’s summary There are now only a few approved vaccines for capsular group B meningococcus (MenB), and their cost effectiveness could be improved upon. To that end, Dold et al. developed an adenoviral-vectored MenB vaccine, ChAdOx1 MenB.1, and tested its safety and immunogenicity in a clinical trial enrolling healthy adults. The authors found that the vaccine was safe and elicited immunity against the homologous bacteria, proving the proof of concept with this approach.
Open in Who Shared Issue with article?
See all 1 articles